Closely-held Soricimed Biopharma has reached its target enrollment and treatment duration in a Phase 1 trial to evaluate the safety and tolerability of SOR-C13 in patients with solid tumor cancers who have failed other...
Closely-held BioSight of Israel reported positive interim results in an abstract at the ASH meeting last week from a Phase 1/2a clinical study of Astarabine in leukemia patients. The aim of the study was to evaluate the...
BTIG has launched coverage of OraSure Technologies (NASDAQ:OSUR) with a “buy” rating and price target of $8. The stock closed at $6.19 on Friday. “A profitable small-cap diagnostics company is a rare find,” writes...
Each year, Piper Jaffray asks its analysts to provide the one name in their universe where they believe they have a differentiated opinion, high conviction and see catalysts ahead in the coming year.Piper Jaffray’s Top...
The FDA’s Psychopharmacologic Drugs Advisory Committee has scheduled a meeting on Jan. 12 to review the NDA for Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine for the maintenance treatment of opioid addiction. The FDA...
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTCQB:OPLI), has completed enrollment of 88 patients in its Phase 2 trial of CF101, an oral treatment for glaucoma. The trial is being conducted in...
Roth Capital Partners has raised its price target on “buy-rated” Titan Pharmaceuticals (NASDAQ:TTNP) to $7.25 from $6.50 to reflect an increased value attributed to Titan’s pipeline. The stock closed at $4.92 on...
Closely-held Ciclofilin Pharmaceuticals has assembled a world-class team of scientists and clinicians for its scientific advisory board (SAB) to guide the company through its drug development program for its lead drug...
Carol Ann Werther has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.Ms. Werther joins HCW with over 20 years of experience in the biotechnology sector...
H.C. Wainwright has raised its price target on “buy-rated” Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) to $6 from $4. The stock closed at $3.23 on Friday. “In our view, the company’s piclidenoson programs remain the...